LONZA N | 531.80 / -1.85% |
Date/Time | 03/09 / 09:21 |
Chg. / Chg.(%) | -10.00 / -1.85% |
Bid | 532.00 / 100 |
Ask | 532.20 / 96 |
Open | 537.80 |
Previous Close | 541.80 |
High | 539.40 |
Low | 531.80 |
Volume [CHF] | 10,794,127.60 |
Volume [Units] | 20,172 |
Price fixings | 672 |
ISIN | CH0013841017 |
Security | LONN |
Exchange | SIX Swiss Exchange |
Type | Stock |
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 531.80 | ![]() |
20,172 |
Cboe Europe .. | 531.80 | ![]() |
1,897 |
Cboe Europe .. | 532.00 | ![]() |
522 |
Turquoise | 532.00 | ![]() |
477 |
London Inter.. | 533.60 | ![]() |
82 |
Lang & Schwa.. | 477.000 | ![]() |
|
Nasdaq Other.. | 582.3700 | ![]() |
34 |
Mexico | 13,094.14 | ![]() |
375 |
TradeGate | 294.000 | 298 | |
Frankfurt | 293.9000 | 63 | |
Düsseldorf | 291.20 | 0 | |
München | 291.30 | 0 | |
Berlin | 296.90 | 0 | |
Hamburg | 291.30 | 0 | |
gettex | 296.100 | ||
Singapore | 79.97 | 500 | |
EUREX | Options |
News
- Arbor Biotechnologies Names Mark D. Angelino to its Board of Directors
03/03/2021 / 14:00 - GlobeNewswire - Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
01/12/2021 / 15:05 - GlobeNewswire - Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
01/08/2021 / 13:00 - GlobeNewswire - Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
12/23/2020 / 14:00 - GlobeNewswire - Recro Announces Executive Changes
12/16/2020 / 13:00 - GlobeNewswire